ArticleScientific reports2018
S100B immunization triggers NFκB and complement activation in an autoimmune glaucoma model.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 50 citations in OpenAlex.
- Cytokines in age-related eye diseases: pathogenesis and potential targets for innovative therapies.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Intermittent fasting reduces glaucomatous damage in an HSP27 autoimmune mouse model.Frontiers in cellular neuroscience · 2025Article
- Challenging glaucoma with emerging therapies: an overview of advancements against the silent thief of sight.Frontiers in medicine · 2025Review
- The Identification of New Pharmacological Targets for the Treatment of Glaucoma: A Network Pharmacology Approach.Pharmaceuticals (Basel, Switzerland) · 2024Article
- A Preliminary Investigation of the Roles of Endometrial Cells in Endometriosis Development via In Vitro and In Vivo Analyses.International journal of molecular sciences · 2024Article
- The Role of Complement Dysregulation in Glaucoma.International journal of molecular sciences · 2024Review
- In a novel autoimmune and high-pressure glaucoma model a complex immune response is induced.Frontiers in immunology · 2024Article
- Retinal Aging Transcriptome and Cellular Landscape in Association With the Progression of Age-Related Macular Degeneration.Investigative ophthalmology & visual science · 2023Article
- Cognitive impairments in a Down syndrome model with abnormal hippocampal and prefrontal dynamics and cytoarchitecture.iScience · 2023Article
- Astrocyte Immune Functions and Glaucoma.International journal of molecular sciences · 2023Review
- Regulatory mechanisms of retinal ganglion cell death in normal tension glaucoma and potential therapies.Neural regeneration research · 2023Review
- HSP27 induced glaucomatous damage in mice of young and advanced age.Frontiers in cellular neuroscience · 2023Article
- Heat Shock Protein Upregulation Supplemental to Complex mRNA Alterations in Autoimmune Glaucoma.Biomolecules · 2022Article
- Review
- Extracorporeal Shock Wave Therapy Combined with Platelet-Rich Plasma during Preventive and Therapeutic Stages of Intrauterine Adhesion in a Rat Model.Biomedicines · 2022Article
- Systemic Treatment with Pioglitazone Reverses Vision Loss in Preclinical Glaucoma Models.Biomolecules · 2022Article
- Enhanced glaucomatous damage accompanied by glial response in a new multifactorial mouse model.Frontiers in immunology · 2022Article
- Article
- Antibody and Protein Profiles in Glaucoma: Screening of Biomarkers and Identification of Signaling Pathways.Biology · 2021Review
- Rat retinae data for use as spectral library, for pathway remodeling as well as protein mapping.Data in brief · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
In glaucoma, latest studies revealed an involvement of the complement system with and without an elevated intraocular pressure. In the experimental autoimmune glaucoma model, immunization with antigens, such as S100B, lead to retinal ganglion cell (RGC) loss and optic nerve degeneration after 28 days. Here, we investigated the timeline of progression of the complement system, toll-like-receptor 4 (TLR4), and the transcription factor nucleus factor-kappa B (NFκB). Therefore, rats were immunized with S100B protein (S100) and analyzed at 3, 7, and 14 days. RGC numbers were comparable at all points in time, whereas a destruction of S100 optic nerves was noted at 14 days. A significant increase of mannose binding lectin (MBL) was observed in S100 retinas at 3 days. Subsequently, significantly more MBL
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.